Profile
Timothy Charles Melkus served as Vice President-Business Development at NeoPharm, Inc. from 2006 to 2007.
He then worked as Senior Vice President-Development Operations at Veloxis Pharmaceuticals A from 2010 to 2012.
Prior to that, he was SVP-Business Development & Operations at IDM Pharma, Inc. Mr. Melkus received his undergraduate degree and MBA from Northwestern University.
Former positions of Timothy Charles Melkus
Companies | Position | End |
---|---|---|
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | Corporate Officer/Principal | 31/05/2007 |
VELOXIS PHARMACEUTICALS A/S | Chief Operating Officer | - |
IDM Pharma, Inc.
IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | Chief Operating Officer | - |
Training of Timothy Charles Melkus
Northwestern University | Masters Business Admin |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
IDM Pharma, Inc.
IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | Health Technology |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | Health Technology |
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
- Stock Market
- Insiders
- Timothy Charles Melkus